Why African ancestry matters in tauopathy research

Most conversations about Alzheimer's disease and related tauopathies still lean on datasets that barely reflect human genetic diversity. That is not a footnote; it is a structural blind spot.

The gap is the finding

When we study tau pathology almost exclusively in populations of European ancestry, we risk mistaking population-specific patterns for universal biology. African ancestry carries distinct genetic architecture — and distinct environmental and health-system contexts that interact with disease trajectories.

What we are building

At Sussex and through collaborations in Nigeria, our work asks a simple question with hard implications: what changes when we centre under-represented ancestries in iPSC and post-mortem studies?

The answer is not only scientific. It affects trial design, biomarker validation, and who benefits first from the next generation of therapies.

A glimpse forward

Science communication across Africa is part of the same mission. Capacity building — BioRTC, training pipelines, open methods — turns representation from a statistic into a sustained practice.

If you are funding, collaborating, or training in this space: the bottleneck is no longer awareness. It is sustained investment in people and infrastructure.